Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma
Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy
Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
DRUG: clarithromycin and lenalidomide
Tumor response assessment, The primary outcome measure is tumour response assessed according to the Revised Response Criteria for Malignant Lymphoma, either clinically (including appropriate imaging procedures) or endoscopically and histologically (in patients affected by gastric lymphoma, according to the GELA scoring system)., During the active treatment period after the 3rd cycles of both drugs administration
Adverse Events assessments, 1. Treatment-emergent adverse events (AEs) incidence, severity and relationship to study treatment.
2. Time from first IMP administration to assessment of disease progression or death due to any cause, whichever occurs earlier., During the active treatment period
Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy